The Globe and Mail reports in its Thursday, Aug. 4, edition that with "mounting recessionary concerns and rising rates," Desjardins Securities analyst Jerome Dubreuil predicts "a period of capital preservation ahead" for health care companies in his coverage universe. The Globe's David Leeder writes that Mr. Dubreuil says: "Although healthcare is resilient relative to other industries, access to capital markets has deteriorated and caused our coverage companies to increasingly focus on profitable growth, which may not be all that bad long-term. ... We believe concerns on churn/the slowdown related to the reopening of the economy are overblown." Mr. Dubreuil continues to rate Dialogue Health Technologies "buy." He cut his share target by $2.50 to $7.50. Analysts on average target the shares at $7.61. Mr. Dubreuil says in a note: "Margins reported last quarter were disappointing given the company had recorded costs related to the Scotiabank onboarding but began generating revenue only in 2Q22; profitability should therefore have improved. ... We believe the company understands that having a sustainable, self-financed business will put it in a position to better capture opportunities."